Members of the Minnesota COVID Ethics Collaborative (MCEC) and key partners in the Minnesota Department of Health (MDH) have published a new article in Mayo Clinic Proceedings on the development of an ethical framework for Minnesota’s allocation of remdesivir, an experimental drug used to treat COVID-19. The authors illuminate the “real-time” bioethics process used to cope with urgent need, resource scarcity, and a still-emerging evidence base. The article can help other states and agencies determine how to allocate remdesivir. MCEC is co-led by Profs. Debra DeBruin at the University’s Center for Bioethics and Susan M. Wolf at the Consortium.
Monday, June 15, 2020